abrdn plc Acquires 186,215 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

abrdn plc boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 552.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 219,900 shares of the biopharmaceutical company's stock after buying an additional 186,215 shares during the quarter. abrdn plc owned approximately 0.20% of Regeneron Pharmaceuticals worth $193,136,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $697,296,000. FMR LLC boosted its position in shares of Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company's stock worth $8,098,661,000 after buying an additional 669,517 shares during the period. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company's stock worth $519,148,000 after buying an additional 590,314 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 57,848.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company's stock worth $420,184,000 after purchasing an additional 581,379 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Regeneron Pharmaceuticals by 129.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company's stock worth $190,170,000 after purchasing an additional 122,103 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 0.3 %

Shares of Regeneron Pharmaceuticals stock traded up $2.83 on Friday, hitting $896.82. 507,466 shares of the company traded hands, compared to its average volume of 412,356. The company has a 50-day moving average price of $953.01 and a 200 day moving average price of $891.67. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The company has a market cap of $98.43 billion, a PE ratio of 25.81, a PEG ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals's revenue for the quarter was up .6% on a year-over-year basis. During the same period in the prior year, the company posted $10.96 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.59 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the company's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the company's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the company's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company's stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,729 shares of company stock worth $13,124,641. Corporate insiders own 8.83% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on REGN shares. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a report on Wednesday, March 13th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an "outperform" rating in a report on Monday, February 5th. Truist Financial reaffirmed a "buy" rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Finally, Bank of America upped their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an "underperform" rating in a report on Friday, April 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $976.41.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.